Key Takeaways
- The US FDA has approved a new pill, Lipfendra, developed by Merck.
- Lipfendra reduces bad cholesterol levels more effectively than statins alone.
- It works by blocking the liver protein PCSK9 and is expected to benefit millions of Pakistanis.
The United States Food and Drug Administration (FDA) has approved a groundbreaking new pill, Lipfendra, developed by Merck, which can drastically reduce bad cholesterol levels among patients. This non-injectable drug targets the liver protein PCSK9, offering an alternative to expensive injectable treatments that have been available for over a decade.
Unlike statins, which are standard medications used to lower the risk of heart attacks but may not be sufficient for all high-risk patients, Lipfendra provides a more effective solution. In clinical trials involving 3,000 high-risk patients, those taking the pill recorded a reduction of over 55 percent in their low-density lipoprotein (LDL) cholesterol levels after six months.
The benefits of Lipfendra were further confirmed in another study where participants experienced an average reduction of 59 percent compared to those who received a placebo. The effectiveness of the treatment declined only slightly over one year, maintaining its efficacy for extended periods.
While side effects such as dizziness and diarrhea were reported at similar rates among people taking Lipfendra and those receiving a placebo, it must be taken on an empty stomach. This requirement could pose challenges for patients who need to adhere strictly to the medication schedule.
The approval of Lipfendra was expedited through a program designed to provide extremely fast reviews for drugs that serve public interest. This rapid approval process highlights the potential impact of the pill in reducing heart attack risks among millions of Pakistanis, many of whom currently struggle with high cholesterol despite taking statins.
Drugs targeting PCSK9 have been available from Amgen and other pharmaceutical companies for over a decade but remained inaccessible due to high prices, insurance restrictions, and low prescribing rates. The non-injectable nature of Lipfendra is expected to increase accessibility and affordability, making it a significant advancement in cholesterol management.
Merck’s approval comes after conducting two studies involving high-risk patients who added the pill to their existing treatments, including statins. This combination therapy could offer a more comprehensive approach to managing cholesterol levels, potentially reducing the risk of heart attacks for millions of Pakistanis.
